MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

130.29 -3.34 (-2.50%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,735,449
Open 131.54
Bid (Size) 130.27 (200)
Ask (Size) 130.33 (100)
Prev. Close 133.64
Today's Range 129.28 - 132.32
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+7.2%
+7.2%
1 Month
-5.7%
-5.7%
3 Month
-0.6%
-0.6%
6 Month
+7.9%
+7.9%
1 Year
+22.5%
+22.5%

More News

Read More
News headline image
What's Going On With Arcus Biosciences Stock On Wednesday? ↗
Via Benzinga
News headline image
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
Via Investor's Business Daily
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗
Via Chartmill
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
From Gilead Sciences, Inc.
Via Business Wire
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
News headline image
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
Via MarketMinute
Topics Bonds
News headline image
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗
Via Benzinga
News headline image
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Via MarketMinute
News headline image
Gilead Extends Tender Offer to Acquire Arcellx
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences's Q1 2026 Earnings: What to Expect
Via Barchart.com
Topics ETFs Workforce
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
Via MarketMinute
News headline image
Options Action: Naked Put Trade Ideas for March 31
Via Barchart.com
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗
Via Benzinga
News headline image
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
3 Reasons to Avoid GILD and 1 Stock to Buy Instead
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 130.29
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 04/24/26 02:41 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 163.37B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 163B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story